Relationship between P-glycoprotein expression and p53 status in high-grade osteosarcoma

International Journal of Oncology

Volumn 14, Issue 2, 1999, Pages 301-307

  Serra, Massimo ^a  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

Author keywords

MDM2; Multidrug resistance; Osteosarcoma; P glycoprotein; p53

Indexed keywords

GLYCOPROTEIN P; PROTEIN P53; TUMOR MARKER;

ADOLESCENT; ADULT; ARTICLE; BIOSYNTHESIS; BONE TUMOR; CHILD; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; METASTASIS; OSTEOSARCOMA; PATHOLOGY; PROGNOSIS;

ADOLESCENT; ADULT; BONE NEOPLASMS; CHILD; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NEOPLASM METASTASIS; OSTEOSARCOMA; P-GLYCOPROTEIN; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033071040     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.14.2.301     Document Type: Article

References (14)

1. Bradley G, Juranka PF and Ling V: Mechanisms of multidrug resistance. Biochim Biophys Acta 948: 87-128, 1988.
2. Gottesman MM and Pastan I: Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62: 385-427, 1993.
3. Morrow CS and Cowan KH: Mechanisms and clinical significance of multidrug resistance. Oncology 2: 55-63, 1988.
4. Goldstein LJ, Galski H, Fojo A, Willingham M, Lai S-L, Gazdar A, Pirker R, Green A, Crist W, Brodeur GM, Lieber M, Cossman J, Gottesman MM and Pastan I: Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 81: 116-124, 1989.
5. Baldini N, Scotlandi K, Barbanti-Bròdano G, Manara MC, Maurici D, Bacci G, Bertoni F, Picci P, Sottili S, Campanacci M and Serra M: Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Eng J Med 333: 1380-1385, 1995.
6. Chan HSL, Grogan TM, Haddad G, DeBoer G and Ling V: P-glycoprotein expression: critical determinant in the response to osteosarcoma chemotherapy. J Natl Cancer Inst 89: 1706-1715, 1997.
7. Chin K-W, Ucda K, Pastan I and Gottesman MM: Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 255: 459-462, 1992.
8. Strauss BE, Shivakumar C, Deb SP, Deb S and Haas M: The MDR1 downstream promoter contains sequence-specific binding sites for wild-type p53. Biochem Biophys Res Commun 217: 825-831, 1995.
9. Lowe SW, Earl Ruley H, Jacks T and Housman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967, 1993.
10. Aas T, Borresen A-L, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug JE, Akslen LA and Lonning PE: Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 2: 811-814, 1996.
11. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE and Jacks T: p53 status and the efficacy of cancer therapy in vivo. Science 266: 807-810, 1994.
12. Olincr JD, Kinzler KW, Meltzer PS, George DL and Vogelstein B: Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358: 80-83, 1992.
13. Toguchida J, Yamaguchi T, Ritchie B, Beauchamp RL, Dayton SH, Herrera GE, Yamamuro T, Kotoura Y, Sasaki MS, Little JB, Weichselbaum RR, Ishizaki K and Yandell DW: Mutation spectrum of the p53 gene in bone and soft tissue sarcomas. Cancer Res 52: 6194-6199, 1992.
14. Soini Y, Vähäkangas K, Kyösti N, Kamel D, Lane DP and Pääkkö P: p53 immunohistochemistry in malignant fibrous histiocytomas and other mesenchymal tumours. J Pathol 168: 29-33, 1992.